2-(4-hydroxymethyl-2,6-dichlorophenylimino)imidazolidine | 86861-24-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-hydroxymethyl-2,6-dichlorophenylimino)imidazolidine
• 英文别名: [3,5-dichloro-4-(4,5-dihydro-1H-imidazol-2-ylamino)-phenyl]-methanol；2-(2,6-dichloro-4-hydroxymethylphenylimino)imidazolidine；[3,5-dichloro-4-(4,5-dihydro-1H-imidazol-2-ylamino)phenyl]methanol
• CAS: 86861-24-7
• 化学式: C₁₀H₁₁Cl₂N₃O
• 分子量: 260.123
• InChiKey: PPGBMYWBCYHNFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.6
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-(4-hydroxymethyl-2,6-dichlorophenylimino)imidazolidine 在 二溴亚砜 作用下， 以 1,2-二氯乙烷 为溶剂， 生成 (4-Bromomethyl-2,6-dichloro-phenyl)-imidazolidin-2-ylidene-amine
  参考文献：
  名称：

  Zhang, Wei-Yi; Bakthavachalam, Venkatesalu; Gao, Yigong, Heterocycles, 1994, vol. 39, # 1, p. 19 - 22

  摘要：

  DOI：
• 作为产物：
  描述：

  2-(4-carbomethoxy-2,6-dichlorophenylimino)imidazolidine 以 四氢呋喃 、 水 、 乙酸乙酯 为溶剂， 生成 2-(4-hydroxymethyl-2,6-dichlorophenylimino)imidazolidine
  参考文献：
  名称：

  Quaternary amino imidazolidines, compositions and use

  摘要：

  式(I)的化合物：其中R.sup.1和R.sup.2相同或不同，且每个都从卤素、烷基、卤代烷基、烷氧基和烷氧基烷基中选择，R.sup.3、R.sup.4和R.sup.5相同或不同，且每个都是烷基；n为0、1、2或3；Z是一种在药用或兽医学上可接受的阴离子，可保护动物免受由肠道致病性大肠杆菌感染引起的死亡。

  公开号：

  US04505926A1

文献信息

• TREATING INFLAMMATION AND INFLAMMATORY PAIN IN MUCOSA USING MUCOSAL PROLONGED RELEASE BIOADHESIVE THERAPEUTIC CARRIERS
  申请人：BioAlliance Pharma S.A.

  公开号：US20130274306A1

  公开（公告）日：2013-10-17

  The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.

  本发明涉及一种药物组合物，其包括一种α-2肾上腺素能受体激动剂，用于预防或治疗口腔、咽喉和喉黏膜的炎症性疼痛和疾病。在另一方面，本发明提供了黏膜生物粘附缓释载体，用于α-2肾上腺素能受体激动剂的延长和控制释放，可用于预防或治疗口腔黏膜的炎症性疼痛和疾病。
• Imidazoline derivatives
  申请人：BEECHAM GROUP PLC

  公开号：EP0107306A1

  公开（公告）日：1984-05-02

  Compounds of formula (I): wherein R1 and R2 are the same or different and each is selected from halogen, alkyl, haloalkyl, alkoxy and alkoxyalkyl, R3, R4 and R5 are the same or different and each is alkyl; n is 0,1, 2 or 3; and Z is a pharmaceutically or veterinarily acceptable anion, protect animals from death due to enteropathogenic E.coli infection of the gastro-intestinal tract.

  式(I)化合物： 其中 R1 和 R2 相同或不同，各自选自卤素、烷基、卤代烷基、烷氧基和烷氧基烷基、 R3、R4 和 R5 相同或不同，各自为烷基； n 是 0、1、2 或 3；以及 Z 是药学上或兽医学上可接受的阴离子，可防止动物因肠道致病性大肠杆菌感染而死亡。
• Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
  申请人：BioAlliance Pharma

  公开号：EP2165706A1

  公开（公告）日：2010-03-24

  The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. In another aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx.

  本发明涉及一种包含α-2肾上腺素能受体激动剂的药物组合物，用于预防或治疗口腔、咽部和喉部粘膜的炎症性疼痛和疾病。在另一方面，本发明提供了用于延长和控制释放α-2肾上腺素能受体激动剂的粘膜生物粘附缓释载体，该载体可用于粘膜表面，以预防或治疗口腔、咽部和喉部粘膜的炎性疼痛和疾病。
• Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
  申请人：BioAlliance Pharma

  公开号：EP2368549A1

  公开（公告）日：2011-09-28

  The present invention relates to clonidine or its derivatives for the treatment of Hand-Foot Syndrome (HFS) or related pathologies. A pharmaceutical composition comprising at least clonidine or its derivatives for preventing or treating HFS or related pathologies is another embodiment of the invention. In a further aspect, the present invention provides topical formulation for the application of clonidine or its derivatives that can be used on cutaneous surfaces for preventing or treating HFS or related pathologies.

  本发明涉及用于治疗手足综合征（HFS）或相关病症的氯尼替丁或其衍生物。本发明的另一个实施方案是一种药物组合物，至少包含用于预防或治疗 HFS 或相关病症的氯尼替胺或其衍生物。在另一个方面，本发明提供了可用于皮肤表面的氯硝柳胺或其衍生物的外用制剂，用于预防或治疗 HFS 或相关病症。
• Clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of chemotherapy
  申请人：ONXEO

  公开号：US10675271B2

  公开（公告）日：2020-06-09

  The present invention pertains to specific clonidine and/or clonidine derivatives for use in the prevention and/or treatment of adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. It also pertains to the use of this clonidine and/or clonidine derivative for the manufacture of a pharmaceutical composition intended to prevent and/or alleviate the adverse side effects of alkylating agent chemotherapy, other than those resulting from mucosal inflammation. This invention is further directed to a kit comprising: (a) a clonidine and/or clonidine derivative, and (b) at least one alkylating chemotherapeutic agent, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.

  本发明涉及用于预防和/或治疗烷化剂化疗不良副作用（粘膜炎症引起的副作用除外）的特定氯尼定和/或氯尼定衍生物。本发明还涉及使用这种氯尼地定和/或氯尼地定衍生物制造药物组合物，以预防和/或减轻烷化剂化疗的不良副作用（粘膜炎症引起的副作用除外）。本发明还涉及一种试剂盒，包括：(a)一种氯尼地定和/或氯尼地定衍生物，和(b)至少一种烷化剂化疗药，作为一种联合制剂，可同时、单独或依次用于治疗癌症。